Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.
2.

Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.

Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG.

Am J Surg Pathol. 2005 Mar;29(3):354-8.

PMID:
15725804
3.

Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A.

Breast Cancer Res. 2001;3(3):183-91. Epub 2001 Feb 1.

4.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
5.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
6.
7.

Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.

Alvarado-Cabrero I, Alderete-Vázquez G, Quintal-Ramírez M, Patiño M, Ruíz E.

Ann Diagn Pathol. 2009 Jun;13(3):151-7. doi: 10.1016/j.anndiagpath.2009.02.003. Epub 2009 Apr 1.

PMID:
19433292
8.

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Uematsu T, Kasami M, Watanabe J, Takahashi K, Yamasaki S, Tanaka K, Tadokoro Y, Ogiya A.

Breast Cancer. 2011 Oct;18(4):309-13. doi: 10.1007/s12282-010-0211-z. Epub 2010 Jun 24.

PMID:
20574730
9.

Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.

Cancer J Sci Am. 1998 Mar-Apr;4(2):125-31.

PMID:
9554929
10.

A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.

Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.

Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26.

PMID:
23890870
11.
12.
13.

Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.

Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y, Alacacioglu A, Cokmert S, Can A, Akyol M, Dirican A, Bayoglu V, Sari AA, Tarhan MO.

Clin Exp Metastasis. 2013 Dec;30(8):1047-62. doi: 10.1007/s10585-013-9602-9. Epub 2013 Jul 9.

PMID:
23836289
14.

Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.

Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE.

Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6.

PMID:
9689981
15.

Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.

Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.

J Cancer Res Clin Oncol. 2010 Feb;136(2):233-41. doi: 10.1007/s00432-009-0654-9. Epub 2009 Aug 14.

PMID:
19685074
16.

Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.

Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP.

Cancer. 2010 Mar 1;116(5):1243-51. doi: 10.1002/cncr.24887.

17.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE.

J Clin Oncol. 1999 Feb;17(2):460-9.

PMID:
10080586
18.

[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].

Li Q, Xu BH, Zhang P, Li Q, Yuan P, Wang JY, Luo Y, Ma F, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010. Chinese.

PMID:
23880002
19.

[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.

Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):858-62. Chinese.

PMID:
20137353
20.

Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.

Solá M, Margelí M, Castellá E, Cirauqui B, Mariscal A, Rull M, Julian JF, Luna M, Vallejo V, Fraile M.

Breast. 2013 Oct;22(5):908-13. doi: 10.1016/j.breast.2013.04.014. Epub 2013 May 15.

PMID:
23683695

Supplemental Content

Support Center